Literature DB >> 8217128

A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.

P Zwirner1, T Murry, G E Woodson.   

Abstract

To assess the efficacy of bilateral or unilateral botulinum treatments for spasmodic dysphonia we injected botulinum toxin (type A) into the thyroarytenoid muscle of 24 patients with adductor type spasmodic dysphonia. Eleven patients underwent unilateral procedures and 13 bilateral procedures. Samples of sustained phonation were analyzed acoustically by a computer-assisted method and the air flow rates determined. All tests were conducted 1 week before injection and 1 week and 1 month after treatment. With unilateral injection, improvements in acoustic parameters occurred as early as 1 week after treatment. With bilateral injections, only the voice break factor was significantly reduced after 1 week, while standard deviations of fundamental frequency, jitter, shimmer and signal-to-noise-ratios were reduced 1 month after treatment. In comparison with unilateral injections, the mean air flow rate was twice as high 1 week after bilateral injections, with no significant differences found 1 month after treatment. Clinically, both injection modes resulted in the reduction of laryngeal spasms as early as within 48 h after injection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217128     DOI: 10.1007/bf00186224

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  16 in total

1.  Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.

Authors:  P Zwirner; T Murry; M Swenson; G E Woodson
Journal:  Laryngoscope       Date:  1992-04       Impact factor: 3.325

2.  Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects.

Authors:  A E Aronson; J R Brown; E M Litin; J S Pearson
Journal:  J Speech Hear Disord       Date:  1968-08

3.  Spasmodic dysphonia: a clinical perspective.

Authors:  D D Rabuzzi; G N McCall
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1972 May-Jun

4.  Intrinsic laryngeal muscle activity in a spastic dysphonia patient.

Authors:  T Shipp; K Izdebski; C Reed; P Morrissey
Journal:  J Speech Hear Disord       Date:  1985-02

5.  Botulinum toxin: mechanism of presynaptic blockade.

Authors:  I Kao; D B Drachman; D L Price
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

6.  Symptom improvement of spastic dysphonia in response to phonatory tasks.

Authors:  C S Bloch; M Hirano; W J Gould
Journal:  Ann Otol Rhinol Laryngol       Date:  1985 Jan-Feb       Impact factor: 1.547

7.  Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection.

Authors:  A E Aronson; L W De Santo
Journal:  Laryngoscope       Date:  1983-01       Impact factor: 3.325

8.  Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report.

Authors:  R H Miller; G E Woodson; J Jankovic
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-06

Review 9.  Neuropathology of spasmodic dysphonia.

Authors:  S D Schaefer
Journal:  Laryngoscope       Date:  1983-09       Impact factor: 3.325

10.  Laryngeal dystonia: a series with botulinum toxin therapy.

Authors:  A Blitzer; M F Brin
Journal:  Ann Otol Rhinol Laryngol       Date:  1991-02       Impact factor: 1.547

View more
  6 in total

1.  Spasmodic dysphonia as a presenting symptom of spinocerebellar ataxia type 12.

Authors:  Jessica Rossi; Francesco Cavallieri; Giada Giovannini; Carla Budriesi; Annalisa Gessani; Miryam Carecchio; Daniela Di Bella; Elisa Sarto; Jessica Mandrioli; Sara Contardi; Stefano Meletti
Journal:  Neurogenetics       Date:  2019-06-13       Impact factor: 2.660

2.  Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31-year experience.

Authors:  Amy Stone; Maria E Powell; Kaitlyn Hamers; K Charles Fletcher; David O Francis; Mark S Courey; James L Netterville; C Gaelyn Garrett
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-19

3.  [The dosage of botulinum toxin type B in adductor type spasmodic dysphonia].

Authors:  R Schönweiler; P Zwirner
Journal:  HNO       Date:  2005-02       Impact factor: 1.284

4.  Spasmodic dysphonia, perceptual and acoustic analysis: presenting new diagnostic tools.

Authors:  Denise Irene Siemons-Lühring; Mieke Moerman; Jean-Pierre Martens; Dirk Deuster; Frank Müller; Philippe Dejonckere
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12       Impact factor: 2.503

5.  Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.

Authors:  Tahwinder Upile; Behrad Elmiyeh; Waseem Jerjes; Vyas Prasad; Panagiotis Kafas; Jesuloba Abiola; Bryan Youl; Ruth Epstein; Colin Hopper; Holger Sudhoff; John Rubin
Journal:  Head Face Med       Date:  2009-10-24       Impact factor: 2.151

Review 6.  Botulinum toxin injections for the treatment of spasmodic dysphonia.

Authors:  C C W Watts; R Whurr; C Nye
Journal:  Cochrane Database Syst Rev       Date:  2004
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.